← Back to patent-cliff list
CAS 96-96-8
2-Nitro-p-anisidine
Codes: (XII)1157260-1-b
Application context (from source-drug indications)
Non-small cell lung cancerZongertinibLung cancerZongertinib食道腺癌Zongertinib食管胃结合部肿瘤ZongertinibGastric cancerZongertinibMetastatic breast cancerZongertinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Zongertinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
1-Methyl-1H-1,3-benzimidazol-5-ol→2-Nitro-p-anisidine→Iodomethane→4-Methoxy-N-methyl-2-nitroaniline→4-Methoxy-N1-methylbenzene-1,2-diamine→Aminomethylideneazanium acetate→5-Methoxy-1-methyl-1H-1,3-benzimidazole
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.